Kieren D Marini
Overview
Explore the profile of Kieren D Marini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schott C, Koehne A, Sayles L, Young E, Luck C, Yu K, et al.
Clin Cancer Res
. 2023 Sep;
30(4):849-864.
PMID: 37703185
Purpose: Models to study metastatic disease in rare cancers are needed to advance preclinical therapeutics and to gain insight into disease biology. Osteosarcoma is a rare cancer with a complex...
2.
Kostyrko K, Roman M, Lee A, Simpson D, Dinh P, Leung S, et al.
Nat Commun
. 2023 Jul;
14(1):3966.
PMID: 37407562
KRAS is a frequent driver in lung cancer. To identify KRAS-specific vulnerabilities in lung cancer, we performed RNAi screens in primary spheroids derived from a Kras mutant mouse lung cancer...
3.
Schott C, Koehne A, Sayles L, Young E, Luck C, Yu K, et al.
bioRxiv
. 2023 Jan;
PMID: 36711882
Models to study metastatic disease in rare cancers are needed to advance preclinical therapeutics and to gain insight into disease biology, especially for highly aggressive cancers with a propensity for...
4.
Leong T, Gayevskiy V, Steinfort D, De Massy M, Gonzalez-Rajal A, Marini K, et al.
Oncogene
. 2018 Oct;
38(10):1661-1675.
PMID: 30348992
Our understanding of genomic heterogeneity in lung cancer is largely based on the analysis of early-stage surgical specimens. Here we used endoscopic sampling of paired primary and intrathoracic metastatic tumors...
5.
Marini K, Croucher D, McCloy R, Vaghjiani V, Gonzalez-Rajal A, Hastings J, et al.
Sci Transl Med
. 2018 Jul;
10(451).
PMID: 30045976
Resistance to platinum chemotherapy is a long-standing problem in the management of lung adenocarcinoma. Using a whole-genome synthetic lethal RNA interference screen, we identified activin signaling as a critical mediator...
6.
Tripathi S, Fahrmann J, Celiktas M, Aguilar M, Marini K, Jolly M, et al.
Cancer Res
. 2017 Jun;
77(16):4414-4425.
PMID: 28646020
Despite favorable responses to initial therapy, small-cell lung cancer (SCLC) relapse occurs within a year and exhibits resistance to multiple drugs. Because of limited accessibility of patient tissues for research...
7.
Fleuren E, Vlenterie M, van der Graaf W, Hillebrandt-Roeffen M, Blackburn J, Ma X, et al.
Cancer Res
. 2017 Jun;
77(16):4279-4292.
PMID: 28634201
Despite intensive multimodal treatment of sarcomas, a heterogeneous group of malignant tumors arising from connective tissue, survival remains poor. Candidate-based targeted treatments have demonstrated limited clinical success, urging an unbiased...
8.
Muscat A, Popovski D, Jayasekara W, Rossello F, Ferguson M, Marini K, et al.
Clin Cancer Res
. 2016 Feb;
22(14):3560-70.
PMID: 26920892
Purpose: Malignant rhabdoid tumor (MRT) and atypical teratoid rhabdoid tumors (ATRT) are rare aggressive undifferentiated tumors primarily affecting the kidney and CNS of infants and young children. MRT are almost...
9.
Leong T, Marini K, Rossello F, Jayasekara S, Russell P, Prodanovic Z, et al.
PLoS One
. 2014 Sep;
9(9):e106862.
PMID: 25191746
Patient-derived xenograft (PDX) models generated from surgical specimens are gaining popularity as preclinical models of cancer. However, establishment of PDX lines from small cell lung cancer (SCLC) patients is difficult...
10.
Rossello F, Tothill R, Britt K, Marini K, Falzon J, Thomas D, et al.
PLoS One
. 2013 Oct;
8(9):e74432.
PMID: 24086345
Next-generation sequencing (NGS) studies in cancer are limited by the amount, quality and purity of tissue samples. In this situation, primary xenografts have proven useful preclinical models. However, the presence...